Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 --0%
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Endava PLC (ADR) (DAVA) to Underperform
- Market Vectors Oil Services ETF (OIH) call put ratio 1.4 calls to 1 put as oil pulls back
- ExxonMobil (XOM) call put ratio 1.4 calls 1 put as oil prices pull back
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
